Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Songhua Huang

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Disability and Rehabilitation|June 21, 2023
Mirror therapy combined with contralaterally controlled functional electrical stimulation for the upper limb motor function after stroke: a randomized controlled trialYuqian Zhang, Xingnan Zhang, Cancan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II TrialQin Xu, Junjie Wang, Yang Sun, et al.
Cancer Discovery|November 26, 2025
Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancerQin Xu, Zhengrong Deng, Jing Liu, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Disability and Rehabilitation|June 21, 2023
Mirror therapy combined with contralaterally controlled functional electrical stimulation for the upper limb motor function after stroke: a randomized controlled trialYuqian Zhang, Xingnan Zhang, Cancan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II TrialQin Xu, Junjie Wang, Yang Sun, et al.
Cancer Discovery|November 26, 2025
Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancerQin Xu, Zhengrong Deng, Jing Liu, et al.
Pageof 2